文献速递乳腺癌放疗放疗物理与技术

BRCA突变携带者乳腺癌放疗后辐射相关第二原发恶性肿瘤分析

Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2020-02-19

仅1例发生野内第二原发恶性肿瘤(甲状腺乳头状癌),粗率为受照乳腺/胸壁的0.38%,20年无辐射诱发SPM的Kaplan-Meier估计为99.5%,未发现辐射诱发SPM风险升高的信号。

要点

  • 野内SPM粗率为受照乳腺/胸壁的0.38%,发生率为每1000女性年0.32例。
  • 未发现BRCA携带者放疗后辐射诱发SPM风险升高的信号,支持放疗安全性。

核心结论

  • 在这组最大的BRCA相关乳腺癌放疗队列中,未发现辐射诱发第二原发恶性肿瘤风险升高的信号,风险极低,结果支持BRCA携带者接受放疗的安全性。

研究设计与样本

  • 单中心回顾性队列研究,纳入1991至2012年接受乳腺和/或胸壁放疗(伴或不伴区域淋巴结照射)的BRCA1或BRCA2携带者乳腺癌患者,要求随访≥5年且人口学、肿瘤和放疗数据完整。

主要发现

  • 中位随访10年(范围5-27年,均值11.4年),共3042人年,发生6例SPM,仅1例(甲状腺乳头状癌)位于射野内,于放疗后17年诊断。
  • 野内SPM粗率为受照乳腺或胸壁的0.38%,对应发生率为每1000女性年0.32例。
  • 20年无辐射诱发SPM的Kaplan-Meier估计为99.5%,野外SPM的计算剂量暴露范围为0.1至1 Gy。
  • 无患者发生野内皮肤癌或肉瘤。

临床怎么用

  • 对于BRCA1/2携带者乳腺癌患者,放疗后辐射诱发第二原发恶性肿瘤的绝对风险极低,可作为临床决策中支持保乳术后放疗或预防性放疗安全性的参考信息。

局限性

  • 本研究为单中心回顾性分析,样本量有限,仍需更大队列和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Radiation therapy (RT), a standard breast cancer (BC) treatment modality, is associated with a small increased risk of in-field second primary malignancy (SPM). SPM rates after RT in BRCA mutation carriers have rarely been reported. An elevated risk of SPM would affect the safety of breast conservation for early BC or prophylactic radiation as a method of prevention. We analyzed a population of BRCA carriers irradiated for BC to determine whether there is an elevated rate of SPM. METHODS AND MATERIALS: Patients with BC who were BRCA1 or BRCA2 carriers and were treated with breast and/or chest wall RT with or without regional lymph nodes between 1991 and 2012 at a single institution were retrospectively identified. Only those with ≥5 years of follow-up with adequate demographic, tumor, and radiation data were included. SPMs were recorded, and previously delivered RT doses to the organ and site of malignancy were determined. RESULTS: Two hundred thirty women, of whom 80% carried an Ashkenazi Jewish founder mutation, met entry criteria with 3-dimensional RT delivered to 266 breasts or chest walls, including regional nodes in 110 (41%). With a median follow-up of 10 years (range, 5-27; mean 11.4) comprising 3042 person-years, 6 SPMs developed, of which only 1 (papillary thyroid carcinoma) was within the radiation field (crude rate of 0.38% of irradiated breasts or chest walls), diagnosed 17 years after RT. This corresponds to an incidence of 0.32 per 1000 woman-years. The Kaplan-Meier estimate of 20-year freedom from a radiation-induced SPM is 99.5%. Calculated dose exposure to the out-of-field SPMs ranged from 0.1 to 1 Gy. No patient developed an in-field skin cancer or sarcoma. CONCLUSIONS: In this largest cohort of women treated with radiation therapy for BRCA-associated breast cancer, we identified no signal for an increased risk of radiation-induced SPMs compared with the general BC population, and the risk is extraordinarily small. Although larger cohorts and longer follow-up are needed, these results support the safety of RT in BRCA carriers.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Schlosser S, Rabinovitch R, Shatz Z, et al. Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer. Int J Radiat Oncol Biol Phys. 2020. PMID: 32084523. doi:10.1016/j.ijrobp.2020.02.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。